Browsing Tag
Gossamer Bio Inc.
1 post
Gossamer Bio (Nasdaq: GOSS) secures regulatory-linked funding as seralutinib NDA nears September
The financing can reach US$250 million, but only about US$25 million is scheduled at the initial closing; another US$125 million requires FDA acceptance of the NDA and US$100 million depends on approval-linked warrants.